PRESSING need of precision care in HER2-positive CRC: The ELEPHANT in the room.

Kanwal P S Raghav Jonathan M Loree Edmund S Kopetz

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

While dual-HER2 inhibition has shown promising clinical activity in patients with RAS wild-type HER2-positive metastatic colorectal cancer, predictive biomarkers of response/resistance are less well characterized. Activating HER2/RTK/MAPK genomic alterations appear to blunt the clinical benefit of dual anti-HER2 therapy and may hold a potential albeit partial role in patient selection.

Keyphrases

wild type
metastatic colorectal cancer
signaling pathway
healthcare
palliative care
case report
stem cells
oxidative stress
quality improvement
copy number
gene expression
pi k akt
risk assessment
dna methylation
climate change
cell proliferation
smoking cessation
trauma patients